{"entity":{"id":"nct06038396","kind":"trial","name":"A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of RC118-ADC, Toripalimab and RC148 in advanced solid tumours, run by RemeGen Co., Ltd., now recruiting.","summary":"A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT06038396 by RemeGen Co., Ltd., with 48 participants planned, started 2023-08-03 and due to reach its primary completion in 2026-02-28. Interventions recorded: RC118, Toripalimab and RC148.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06038396","url":"https://clinicaltrials.gov/study/NCT06038396"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["rc118-adc","toripalimab","rc148"],"companies":["remegen"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06038396","phase":"1/2","setting":"A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of RC118 in Combination with Toripalimab / RC148 for Patients with Claudin 18.2-Positive, Locally Advanced Unresectable or Metastatic Malignant Solid Tumors","sponsor":"RemeGen Co., Ltd.","enrolled":48,"outcomes":[]},"route":"/trials/nct06038396/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"rc118-adc","kind":"drug","name":"RC118-ADC","route":"/drugs/rc118-adc/"},{"id":"rc148","kind":"drug","name":"RC148","route":"/drugs/rc148/"},{"id":"toripalimab","kind":"drug","name":"Toripalimab","route":"/drugs/toripalimab/"}],"company":[{"id":"remegen","kind":"company","name":"RemeGen","route":"/companies/remegen/"}]}}